Previous 10 | Next 10 |
Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 million Guiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Sp...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
2024-02-12 22:49:38 ET Summary Liquidia's stock has increased in value by 209.32% since June 2022. Liquidia's PAH drug, Yutrepia, is expected to launch in the first or second quarter of 2024, potentially leading to profitability. Liquidia has gained a major partnership for a s...
MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on March 4 th...
MARLBOROUGH, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company ® , today announced that the newly established Queensland Spatial Biology Centre (QSBC), located in Brisbane, Australia, is using the PhenoCycler-Fusion spatial ...
MARLBOROUGH, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company ® , today announced the establishment of its Scientific Advisory Board (SAB) to provide strategic guidance and consult on the Company's efforts to deliver spatial bi...
2024-01-08 10:56:35 ET More on Akoya Biosciences Akoya Biosciences: 2024 Could Be The Year To Own Their Stock Akoya Biosciences, Inc. (AKYA) Q3 2023 Earnings Call Transcript It's JPM time! Which medtechs are expected to issue updates this week? Seeking Alpha&...
2024-01-08 08:46:55 ET Aclarion ( ACON ) +111% Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan. Harpoon Therapeutics ( HARP ) +110% stock surges as Merck reportedly in talks for $700M acquisition. Ambrx Biopharma ( ...
2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...
MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced that it has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc. The agreement enables Akoya to market the combination...
News, Short Squeeze, Breakout and More Instantly...
Akoya BioSciences Inc. Company Name:
AKYA Stock Symbol:
NASDAQ Market:
Akoya BioSciences Inc. Website:
MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. C...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 367.5% to $0.2852 on volume of 1,515,686,571 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 32.0% to $6.85 on volume of 599,135,465 shares Crown Electrokinetics Corp. (CR...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...